Rheumatoid Arthritis-patient reported outcomes (RA-PRO) study for treatment strategies after methotrexate inadequate-response (MTX-IR)

Brief description of study

RA-PRO is a 12-month, 2-arm, open-label, RCT pragmatic study to test whether adding TNF-biologic strategy is superior to the alternative approach of small molecule Jak-kinase inhibitor in RA patients with active disease despite adequate trial of methotrexate, i.e. MTX-inadequate responder (IR), in a variety of clinical care settings across the U.S. at multiple sites.

Clinical Study Identifier: s21-01161
ClinicalTrials.gov Identifier: NCT04692493
Principal Investigator: Pamela Rosenthal.
Other Investigator: Sara E Stream.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.